



Clinical trial results:

A Phase III, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety, Tolerability, and Immunogenicity of Fluad and Agriflu Compared to the Non Adjuvanted Trivalent Influenza Vaccine Fluzone in Children 6 to <72 Months of Age.

Summary

EudraCT number	2014-005053-40
Trial protocol	Outside EU/EEA
Global end of trial date	27 July 2012

Results information

Result version number	v2 (current)
This version publication date	29 July 2016
First version publication date	01 April 2015
Version creation reason	<ul style="list-style-type: none">• Correction of full data set Required for the re-QC project because of the EudraCT system glitch and possible updates to results may be required. Moreover, a change in system user for this study is necessary.

Trial information

Trial identification

Sponsor protocol code	V70_29
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01346592
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Vaccines and Diagnostic, S.r.l
Sponsor organisation address	Via Fiorentina 1, Siena, Italy, 53100
Public contact	Posting Director, Novartis Vaccines and Diagnostic, S.r.l, RegistryContactVaccinesUS@novartis.com
Scientific contact	Posting Director, Novartis Vaccines and Diagnostic, S.r.l, RegistryContactVaccinesUS@novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	11 July 2013
Is this the analysis of the primary completion data?	Yes
Primary completion date	22 July 2012
Global end of trial reached?	Yes
Global end of trial date	27 July 2012
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To demonstrate the noninferior immunogenicity of 2 intramuscular (IM) doses of Fludax to Agriflu and Fluzone (coprimary) in terms of both seroconversion¹ and geometric mean titers (GMTs), as measured by hemagglutination inhibition (HI) assay in all 3 homologous strains in subjects aged 6 through <72 months.
To demonstrate the noninferiority of 2 IM doses of Agriflu to Fluzone in terms of both seroconversion rates and GMTs, as measured by HI assay in all 3 homologous strains in subjects aged 6 through <36 months.

Protection of trial subjects:

This clinical study was designated, implemented and reported in accordance with the International Conference on Harmonization (ICH) Harmonized Tripartite Guidelines for Good Clinical Practice (GCP), with applicable local regulations (including European Directive 2001/20/EC, US Code of Federal Regulations (CFR) Title 21, and Japanese Ministry of Health, Labor and Welfare), and with the ethical principles laid down in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	09 April 2011
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	1 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Philippines: 4513
Country: Number of subjects enrolled	South Africa: 834
Country: Number of subjects enrolled	Argentina: 552
Country: Number of subjects enrolled	Australia: 161
Country: Number of subjects enrolled	Chile: 40
Worldwide total number of subjects	6100
EEA total number of subjects	0

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	1995
Children (2-11 years)	4105
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

A total of 5750 subjects were planned for this study. Overall, 6104 subjects were enrolled.

Pre-assignment

Screening details:

Subjects were assigned randomly to receive Fluad, Agriflu or Fluzone with allocation ratios 3:2:2 and 4:1:1 for age subgroups 6 to <36 and 36 to <72 months, respectively.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Blinding implementation details:

During the study, unblinded designated qualified health care personnel were responsible for administering the study vaccines to the subjects, and were instructed not to reveal the identity of the study vaccines either to the subject or to the investigative site personnel (investigator, study nurse) involved in the monitoring or conduct of the study, except in an emergency.

Arms

Are arms mutually exclusive?	Yes
Arm title	aTIV (6 to <72 Months)

Arm description:

Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29.

Arm type	Experimental
Investigational medicinal product name	MF59-adjuvanted trivalent influenza vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Single 0.25-mL or a 0.5 mL dose of relevant vaccine was to be administered intramuscularly in the deltoid muscle.

Arm title	Comparator TIV (6 to <72 Months)
------------------	----------------------------------

Arm description:

Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29.

Arm type	Active comparator
Investigational medicinal product name	Licensed comparator Trivalent split influenza vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Single 0.25-mL or a 0.5-mL dose of relevant vaccine was to be administered intramuscularly in the deltoid muscle.

Arm title	TIV (6 to <72 Months)
Arm description:	
Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29.	
Arm type	Experimental
Investigational medicinal product name	Trivalent split influenza vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

Single 0.25-mL or a 0.5-mL dose of relevant vaccine was to be administered intramuscularly in the deltoid muscle.

Number of subjects in period 1	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)
Started	3136	1478	1486
Completed	2983	1389	1408
Not completed	153	89	78
Consent withdrawn by subject	77	51	38
Adverse Event	-	1	-
Death	1	3	4
Lost to follow-up	62	29	29
Unable to Classify	7	3	6
Inappropriate Enrollment	3	1	1
Administrative reason	1	-	-
Protocol deviation	2	1	-

Baseline characteristics

Reporting groups

Reporting group title	aTIV (6 to <72 Months)
Reporting group description:	
Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29.	
Reporting group title	Comparator TIV (6 to <72 Months)
Reporting group description:	
Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29.	
Reporting group title	TIV (6 to <72 Months)
Reporting group description:	
Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29.	

Reporting group values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)
Number of subjects	3136	1478	1486
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	847	574	574
Children (2-11 years)	2289	904	912
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous Units: months			
arithmetic mean	37.1	30	30.2
standard deviation	± 18.6	± 16.9	± 16.9
Gender categorical Units: Subjects			
Female	1545	745	731
Male	1591	733	755

Reporting group values	Total		
Number of subjects	6100		
Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		

Infants and toddlers (28 days-23 months)	1995		
Children (2-11 years)	4105		
Adolescents (12-17 years)	0		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
Age continuous Units: months arithmetic mean standard deviation	-		
Gender categorical Units: Subjects			
Female	3021		
Male	3079		

End points

End points reporting groups

Reporting group title	aTIV (6 to <72 Months)
Reporting group description: Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29.	
Reporting group title	Comparator TIV (6 to <72 Months)
Reporting group description: Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29.	
Reporting group title	TIV (6 to <72 Months)
Reporting group description: Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29.	
Subject analysis set title	FAS Population
Subject analysis set type	Full analysis
Subject analysis set description: All subjects in the Full analysis set who actually received a study vaccination, and provided at least one evaluable serum sample before and after vaccination (for subjects in the immunogenicity subset).	
Subject analysis set title	PPS Population
Subject analysis set type	Per protocol
Subject analysis set description: All subjects in the FAS immunogenicity population who correctly received the vaccine, and provided evaluable serum samples at the relevant time points (for subjects in the immunogenicity subset), and had no major protocol violation as defined prior to unblinding.	
Subject analysis set title	aTIV (6 to <36 Months)
Subject analysis set type	Per protocol
Subject analysis set description: Subjects received two doses (Day 1 & 29) of an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).	
Subject analysis set title	Safety Set
Subject analysis set type	Safety analysis
Subject analysis set description: All subjects who had received at least one study vaccine and had postvaccination safety data were included in the safety analyses.	
Subject analysis set title	Comparator TIV (6 to <36 Months)
Subject analysis set type	Per protocol
Subject analysis set description: Subjects received two doses (Day 1 & 29) of a licensed comparator trivalent split influenza vaccine (comparator TIV).	
Subject analysis set title	TIV (6 to <36 Months)
Subject analysis set type	Per protocol
Subject analysis set description: Subjects received two doses (Day 1 & 29) of an investigational trivalent split influenza vaccine (TIV).	
Subject analysis set title	aTIV (36 to <72 Months)
Subject analysis set type	Per protocol
Subject analysis set description: Subjects received one dose (Day 1) of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).	
Subject analysis set title	TIV (36 to <72 Months)

Subject analysis set type	Per protocol
Subject analysis set description:	
Subjects received one dose (Day1) of an investigational trivalent split influenza vaccine (TIV).	
Subject analysis set title	Comparator TIV (36 to <72 Months)
Subject analysis set type	Per protocol
Subject analysis set description:	
Subjects received one dose (Day 1) of a licensed comparator trivalent split influenza vaccine (comparator TIV).	
Subject analysis set title	aTIV (6 to <24 Months)
Subject analysis set type	Full analysis
Subject analysis set description:	
Subjects received two doses of 0.25 mL each, of the investigational MF59-adjuvanted trivalent split influenza vaccine (aTIV), at Days 1 & 29.	
Subject analysis set title	Comparator TIV (6 to <24 Months)
Subject analysis set type	Full analysis
Subject analysis set description:	
Subjects received two doses of 0.25 mL each, of the licensed comparator trivalent split influenza vaccine (comparator TIV), at Days 1 & 29.	
Subject analysis set title	TIV (6 to <24 Months)
Subject analysis set type	Full analysis
Subject analysis set description:	
Subjects received two doses of 0.25 mL each, of the investigational trivalent split influenza vaccine (TIV), at Days 1 & 29.	

Primary: Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous Strains

End point title	Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous Strains
End point description:	
The non-inferiority of Hemagglutination Inhibition (HI) antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains.	
End point type	Primary
End point timeframe:	
Day 1, Day 50	

End point values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	682	757	765	
Units: Titers				
geometric mean (confidence interval 95%)				
H1N1 - Day 1 (N=681,757,765)	28 (24 to 33)	24 (21 to 28)	27 (23 to 31)	
H1N1 - Day 50 (N=681,757,765)	1537 (1382 to 1709)	629 (567 to 698)	480 (433 to 532)	
H3N2 - Day 1	40 (35 to 47)	42 (36 to 49)	44 (38 to 51)	
H3N2 - Day 50	1908 (1785 to 2040)	1012 (948 to 1080)	803 (752 to 857)	
B strain Day 1	9.87 (9.08 to 11)	10 (9.41 to 11)	10 (9.33 to 11)	

B strain Day 50	492 (450 to 537)	160 (147 to 175)	157 (144 to 171)	
-----------------	------------------	------------------	------------------	--

Statistical analyses

Statistical analysis title	GMT ratio (H1N1 strain)
Comparison groups	Comparator TIV (6 to <72 Months) v aTIV (6 to <72 Months)
Number of subjects included in analysis	1439
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[1]
Parameter estimate	GMT ratio (H1N1 strain)
Point estimate	2.44
Confidence interval	
level	Other: 97.6 %
sides	2-sided
lower limit	2.06
upper limit	2.9

Notes:

[1] - Noninferiority was established if the lower limit of the confidence interval of the day 50 ratio of GMTs was >0.667

Statistical analysis title	GMT ratio (H3N2 strain)
Comparison groups	Comparator TIV (6 to <72 Months) v aTIV (6 to <72 Months)
Number of subjects included in analysis	1439
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[2]
Parameter estimate	GMT ratio (H3N2 strain)
Point estimate	1.89
Confidence interval	
level	Other: 97.6 %
sides	2-sided
lower limit	1.69
upper limit	2.1

Notes:

[2] - Noninferiority was established if the lower limit of the confidence interval of the day 50 ratio of GMTs was >0.667

Statistical analysis title	GMT ratio (B strain)
Comparison groups	Comparator TIV (6 to <72 Months) v aTIV (6 to <72 Months)
Number of subjects included in analysis	1439
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[3]
Parameter estimate	GMT ratio (B strain)
Point estimate	3.07
Confidence interval	
level	Other: 97.6 %
sides	2-sided
lower limit	2.66
upper limit	3.54

Notes:

[3] - Noninferiority was established if the lower limit of the confidence interval of the day 50 ratio of GMTs was >0.667

Statistical analysis title	GMT ratio (H1N1 strain)
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1447
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[4]
Parameter estimate	GMT ratio (H1N1 strain)
Point estimate	3.2
Confidence interval	
level	Other: 97.6 %
sides	2-sided
lower limit	2.7
upper limit	3.8

Notes:

[4] - Noninferiority was established if the lower limit of the confidence interval of the day 50 ratio of GMTs was >0.667

Statistical analysis title	GMT ratio (H3N2 strain)
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1447
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[5]
Parameter estimate	GMT ratio (H3N2 strain)
Point estimate	2.38
Confidence interval	
level	Other: 97.6 %
sides	2-sided
lower limit	2.14
upper limit	2.65

Notes:

[5] - Noninferiority was established if the lower limit of the confidence interval of the day 50 ratio of GMTs was >0.667

Statistical analysis title	GMT ratio (B strain)
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1447
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[6]
Parameter estimate	GMT ratio (B strain)
Point estimate	3.14
Confidence interval	
level	Other: 97.6 %
sides	2-sided
lower limit	2.72
upper limit	3.62

Notes:

[6] - Noninferiority was established if the lower limit of the confidence interval of the day 50 ratio of GMTs was >0.667

Primary: Comparison of Antibody Responses of aTIV With TIV and Comparator TIV

in Terms of Percentage of Subjects Achieving Seroconversion or ≥ 4 -fold Increase in HI Titers Against Homologous Strains

End point title	Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥ 4 -fold Increase in HI Titers Against Homologous Strains
-----------------	---

End point description:

The non-inferiority of HI antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of percentage of subjects achieving seroconversion or ≥ 4 -fold increase in HI titers at three weeks after last vaccination against the three homologous vaccine strains.

End point type	Primary
----------------	---------

End point timeframe:

Day 50

End point values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	682	757	765	
Units: Percentage of subjects				
number (confidence interval 95%)				
H1N1 - (N=680,757,765)	92.9 (90.8 to 94.8)	84.5 (81.8 to 87.1)	79.4 (76.3 to 82.2)	
H3N2	96.5 (94.8 to 97.7)	92.3 (90.2 to 94.1)	89.4 (87 to 91.5)	
B strain	98 (96.6 to 98.9)	86 (83.3 to 88.4)	84.6 (81.8 to 87.1)	

Statistical analyses

Statistical analysis title	Group difference (H1N1 strain)
Comparison groups	Comparator TIV (6 to <72 Months) v aTIV (6 to <72 Months)
Number of subjects included in analysis	1439
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[7]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	9.09
Confidence interval	
level	Other: 97.6 %
sides	2-sided
lower limit	5.48
upper limit	12.69

Notes:

[7] - Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group difference was $> -10\%$.

Statistical analysis title	Group difference (H3N2 strain)
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)

Number of subjects included in analysis	1439
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[8]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	4.07
Confidence interval	
level	Other: 97.6 %
sides	2-sided
lower limit	1.58
upper limit	6.55

Notes:

[8] - Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group difference was >-10%.

Statistical analysis title	Group difference (B strain)
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1439
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[9]
Parameter estimate	Group difference (B strain)
Point estimate	11.82
Confidence interval	
level	Other: 97.6 %
sides	2-sided
lower limit	8.72
upper limit	14.92

Notes:

[9] - Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group difference was >-10%.

Statistical analysis title	Group difference (H1N1 strain)
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1447
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[10]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	14.21
Confidence interval	
level	Other: 97.6 %
sides	2-sided
lower limit	10.3
upper limit	18.13

Notes:

[10] - Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)

Number of subjects included in analysis	1447
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[11]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	7.31
Confidence interval	
level	Other: 97.6 %
sides	2-sided
lower limit	4.47
upper limit	10.14

Notes:

[11] - Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1447
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[12]
Parameter estimate	Group difference (B strain)
Point estimate	11.1
Confidence interval	
level	Other: 97.6 %
sides	2-sided
lower limit	8.11
upper limit	14.1

Notes:

[12] - Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group difference was > -10%.

Primary: Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous Strains (6 to <36 Months)

End point title	Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous Strains (6 to <36 Months)
-----------------	---

End point description:

The non-inferiority of HI antibody responses of TIV to that of comparator TIV, in subjects aged 6 to <36 Months, assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains.

End point type	Primary
----------------	---------

End point timeframe:

Day 1, Day 50

End point values	Comparator TIV (6 to <36 Months)	TIV (6 to <36 Months)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	635	642		
Units: Titers				
geometric mean (confidence interval 95%)				
H1N1 - Day 1	20 (17 to 23)	23 (20 to 27)		

H1N1 - Day 50	487 (431 to 551)	370 (328 to 419)		
H3N2 - Day 1	28 (24 to 33)	29 (24 to 33)		
H3N2 - Day 50	912 (849 to 980)	698 (650 to 749)		
B strain Day 1	9.42 (8.62 to 10)	9.42 (8.63 to 10)		
B -strain Day 50	152 (138 to 168)	144 (130 to 159)		

Statistical analyses

Statistical analysis title	GMT ratio (H1N1 strain)
Comparison groups	TIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)
Number of subjects included in analysis	1277
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[13]
Parameter estimate	GMT ratio (H1N1 strain)
Point estimate	0.76
Confidence interval	
level	Other: 97.4 %
sides	2-sided
lower limit	0.62
upper limit	0.93

Notes:

[13] - Non-inferiority was established if the lower bound of the confidence interval for day 50 GMT group ratios was >0.667

Statistical analysis title	GMT ratio (B strain)
Comparison groups	Comparator TIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1277
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[14]
Parameter estimate	GMT ratio (B strain)
Point estimate	0.94
Confidence interval	
level	Other: 97.4 %
sides	2-sided
lower limit	0.8
upper limit	1.11

Notes:

[14] - Non-inferiority was established if the lower bound of the confidence interval for day 50 GMT group ratios was >0.667

Statistical analysis title	GMT ratio (H3N2 strain)
Comparison groups	Comparator TIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1277
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[15]
Parameter estimate	GMT ratio (H3N2 strain)
Point estimate	0.77
Confidence interval	
level	Other: 97.4 %
sides	2-sided
lower limit	0.68
upper limit	0.86

Notes:

[15] - Non-inferiority was established if the lower bound of the confidence interval for day 50 GMT group ratios was >0.667

Secondary: Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥ 4 -fold Increase in HI Titer Against Homologous Strains in Subjects 6 to <36 Months of Age

End point title	Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥ 4 -fold Increase in HI Titer Against Homologous Strains in Subjects 6 to <36 Months of Age
-----------------	--

End point description:

The non-inferiority of HI antibody responses of TIV to that of the licensed comparator TIV assessed in terms of percentage of subjects achieving seroconversion or ≥ 4 -fold increase in HI titers at three weeks after last vaccination against the three homologous vaccine strains.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 50

End point values	Comparator TIV (6 to <36 Months)	TIV (6 to <36 Months)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	635	642		
Units: Percentage of subjects				
number (confidence interval 95%)				
H1N1	84.1 (81 to 86.9)	78.8 (75.5 to 81.9)		
H3N2	92.6 (90.3 to 94.5)	89.9 (87.3 to 92.1)		
B Strain	85.5 (82.5 to 88.2)	82.7 (79.6 to 85.6)		

Statistical analyses

Statistical analysis title	Group difference (H1N1 strain)
Comparison groups	Comparator TIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1277
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[16]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	-5.3
Confidence interval	
level	Other: 97.4 %
sides	2-sided
lower limit	-10.13
upper limit	-0.47

Notes:

[16] - Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group differences was > -10%

Statistical analysis title	Group difference (H3N2 strain)
Comparison groups	Comparator TIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1277
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[17]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	-2.84
Confidence interval	
level	Other: 97.4 %
sides	2-sided
lower limit	-6.16
upper limit	0.5

Notes:

[17] - Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group differences was > -10%

Statistical analysis title	Group difference (B strain)
Comparison groups	Comparator TIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1277
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[18]
Parameter estimate	Group difference (B strain)
Point estimate	-2.49
Confidence interval	
level	Other: 97.4 %
sides	2-sided
lower limit	-7.01
upper limit	2

Notes:

[18] - Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group differences was > -10%

Secondary: Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains (6 to <24 Months)

End point title	Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains (6 to <24 Months)
-----------------	--

End point description:

Analysis was done on the Full Analysis Set.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1, Day 50

End point values	aTIV (6 to <24 Months)	Comparator TIV (6 to <24 Months)	TIV (6 to <24 Months)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	266	389	387	
Units: Titers				
geometric mean (confidence interval 95%)				
H1N1 - Day 1	12 (9.52 to 14)	9.87 (8.36 to 12)	12 (9.95 to 14)	
H1N1 - Day 50	1080 (899 to 1297)	298 (256 to 347)	205 (176 to 238)	
H3N2 - Day 1	15 (12 to 19)	15 (12 to 18)	17 (14 to 21)	
H3N2 - Day 50	1709 (1536 to 1903)	758 (694 to 828)	552 (505 to 603)	
B strain Day 1	7.75 (6.83 to 8.78)	8.18 (7.37 to 9.07)	7.92 (7.14 to 8.79)	
B strain Day 50	616 (534 to 711)	133 (118 to 149)	112 (100 to 127)	

Statistical analyses

Statistical analysis title	GMT ratio (H1N1 strain)
Comparison groups	aTIV (6 to <24 Months) v Comparator TIV (6 to <24 Months)
Number of subjects included in analysis	655
Analysis specification	Pre-specified
Analysis type	superiority ^[19]
Parameter estimate	GMT ratio (H1N1 strain)
Point estimate	3.63
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.86
upper limit	4.6

Notes:

[19] - Superiority was concluded if the lower limit of the confidence interval for the day 50 vaccine group GMT ratios for at least 2 homologous strains was >1.5.

Statistical analysis title	GMT ratio (H3N2 strain)
Comparison groups	aTIV (6 to <24 Months) v Comparator TIV (6 to <24 Months)

Number of subjects included in analysis	655
Analysis specification	Pre-specified
Analysis type	superiority ^[20]
Parameter estimate	GMT ratio (H3N2 strain)
Point estimate	2.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.96
upper limit	2.59

Notes:

[20] - Superiority was concluded if the lower limit of the confidence interval for the day 50 vaccine group GMT ratios for at least 2 homologous strains was >1.5.

Statistical analysis title	GMT ratio (B strain)
Comparison groups	aTIV (6 to <24 Months) v Comparator TIV (6 to <24 Months)
Number of subjects included in analysis	655
Analysis specification	Pre-specified
Analysis type	superiority ^[21]
Parameter estimate	GMT ratio (B strain)
Point estimate	4.64
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.86
upper limit	5.59

Notes:

[21] - Superiority was concluded if the lower limit of the confidence interval for the day 50 vaccine group GMT ratios for at least 2 homologous strains was >1.5.

Statistical analysis title	GMT ratio (H1N1 strain)
Comparison groups	aTIV (6 to <24 Months) v TIV (6 to <24 Months)
Number of subjects included in analysis	653
Analysis specification	Pre-specified
Analysis type	superiority ^[22]
Parameter estimate	GMT ratio (H1N1 strain)
Point estimate	5.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.16
upper limit	6.7

Notes:

[22] - Superiority was concluded if the lower limit of the confidence interval for the day 50 vaccine group GMT ratios for at least 2 homologous strains was >1.5.

Statistical analysis title	GMT ratio (H3N2 strain)
Comparison groups	aTIV (6 to <24 Months) v TIV (6 to <24 Months)

Number of subjects included in analysis	653
Analysis specification	Pre-specified
Analysis type	superiority ^[23]
Parameter estimate	GMT ratio (H3N2 strain)
Point estimate	3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.69
upper limit	3.56

Notes:

[23] - Superiority was concluded if the lower limit of the confidence interval for the day 50 vaccine group GMT ratios for at least 2 homologous strains was >1.5.

Statistical analysis title	GMT ratio (B strain)
Comparison groups	aTIV (6 to <24 Months) v TIV (6 to <24 Months)
Number of subjects included in analysis	653
Analysis specification	Pre-specified
Analysis type	superiority ^[24]
Parameter estimate	GMT ratio (B strain)
Point estimate	5.48
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.55
upper limit	6.6

Notes:

[24] - Superiority was concluded if the lower limit of the confidence interval for the day 50 vaccine group GMT ratios for at least 2 homologous strains was >1.5.

Secondary: Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains (6 to <24 Months)

End point title	Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains (6 to <24 Months)
-----------------	--

End point description:

Analysis was done on the FAS

End point type	Secondary
----------------	-----------

End point timeframe:

Day 50

End point values	aTIV (6 to <24 Months)	Comparator TIV (6 to <24 Months)	TIV (6 to <24 Months)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	266	389	387	
Units: Percentage of Subjects				
number (confidence interval 95%)				
H1N1	95.5 (92.3 to 97.7)	85.1 (81.2 to 88.5)	77.8 (73.3 to 81.8)	

H3N2	98.1 (95.7 to 99.4)	95.6 (93.1 to 97.4)	92.5 (89.4 to 94.9)	
B strain	98.1 (95.7 to 99.4)	85.4 (81.4 to 88.7)	79.3 (75 to 83.3)	

Statistical analyses

Statistical analysis title	Group difference (H1N1 strain)
Comparison groups	aTIV (6 to <24 Months) v Comparator TIV (6 to <24 Months)
Number of subjects included in analysis	655
Analysis specification	Pre-specified
Analysis type	superiority ^[25]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	10.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.1
upper limit	14.7

Notes:

[25] - Superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference, for at least 2 homologous strains, was >10%.

Statistical analysis title	Group difference (H3N2 strain)
Comparison groups	aTIV (6 to <24 Months) v Comparator TIV (6 to <24 Months)
Number of subjects included in analysis	655
Analysis specification	Pre-specified
Analysis type	superiority ^[26]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	2.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.12
upper limit	5.1

Notes:

[26] - Superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference, for at least 2 homologous strains, was >10%.

Statistical analysis title	Group difference (B strain)
Comparison groups	aTIV (6 to <24 Months) v Comparator TIV (6 to <24 Months)
Number of subjects included in analysis	655
Analysis specification	Pre-specified
Analysis type	superiority ^[27]
Parameter estimate	Group difference (B strain)
Point estimate	12.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.9
upper limit	16.7

Notes:

[27] - Superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference, for at least 2 homologous strains, was >10%.

Statistical analysis title	Group difference (H1N1 strain)
Comparison groups	aTIV (6 to <24 Months) v TIV (6 to <24 Months)
Number of subjects included in analysis	653
Analysis specification	Pre-specified
Analysis type	superiority ^[28]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	17.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.9
upper limit	22.6

Notes:

[28] - Superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference, for at least 2 homologous strains, was >10%.

Statistical analysis title	Group difference (H3N2 strain)
Comparison groups	aTIV (6 to <24 Months) v TIV (6 to <24 Months)
Number of subjects included in analysis	653
Analysis specification	Pre-specified
Analysis type	superiority ^[29]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	5.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.5
upper limit	8.7

Notes:

[29] - Superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference, for at least 2 homologous strains, was >10%.

Statistical analysis title	Group difference (B strain)
Comparison groups	aTIV (6 to <24 Months) v TIV (6 to <24 Months)
Number of subjects included in analysis	653
Analysis specification	Pre-specified
Analysis type	superiority ^[30]
Parameter estimate	Group difference (B strain)
Point estimate	18.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	14.4
upper limit	23.1

Notes:

[30] - Superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference, for at least 2 homologous strains, was >10%.

Secondary: Comparison of Antibody Responses of aTIV With TIV and Comparator

TIV in Terms of GMTs Against Homologous Strains (6 to <72 Months)-FAS

End point title	Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains (6 to <72 Months)-FAS
End point description: Analysis was done on the FAS	
End point type	Secondary
End point timeframe: Day 1, Day 50	

End point values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	747	839	849	
Units: Titers				
geometric mean (confidence interval 95%)				
H1N1 - Day 1 (N=746,839,849)	29 (25 to 33)	24 (21 to 28)	27 (23 to 31)	
H1N1 - Day 50 (N=746,839,849)	1519 (1372 to 1683)	637 (577 to 704)	473 (428 to 522)	
H3N2 - Day 1	41 (36 to 48)	42 (37 to 49)	44 (38 to 50)	
H3N2 - Day 50	1909 (1791 to 2035)	1016 (954 to 1081)	796 (748 to 847)	
B strain - Day 1	9.97 (9.2 to 11)	10 (9.49 to 11)	10 (9.33 to 11)	
B strain-Day 50	480 (441 to 523)	164 (151 to 178)	156 (144 to 169)	

Statistical analyses

Statistical analysis title	GMT Ratio (H1N1 strain)
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1586
Analysis specification	Pre-specified
Analysis type	superiority ^[31]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	2.38
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.07
upper limit	2.75

Notes:

[31] - Superiority was concluded if the lower limit of the confidence interval of the day 50 vaccine group GMT ratios for at least 2 homologous strains was >1.5.

Statistical analysis title	GMT Ratio (H3N2 strain)
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)

Number of subjects included in analysis	1586
Analysis specification	Pre-specified
Analysis type	superiority ^[32]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	1.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.72
upper limit	2.06

Notes:

[32] - Superiority was concluded if the lower limit of the confidence interval of the day 50 vaccine group GMT ratios for at least 2 homologous strains was >1.5.

Statistical analysis title	GMT Ratio (B strain)
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1586
Analysis specification	Pre-specified
Analysis type	superiority ^[33]
Parameter estimate	GMT Ratio (B strain)
Point estimate	2.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.6
upper limit	3.3

Notes:

[33] - Superiority was concluded if the lower limit of the confidence interval of the day 50 vaccine group GMT ratios for at least 2 homologous strains was >1.5.

Statistical analysis title	GMT Ratio (H1N1 strain)
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1596
Analysis specification	Pre-specified
Analysis type	superiority ^[34]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	3.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.79
upper limit	3.71

Notes:

[34] - Superiority was concluded if the lower limit of the confidence interval of the day 50 vaccine group GMT ratios for at least 2 homologous strains was >1.5.

Statistical analysis title	GMT Ratio (H3N2 strain)
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)

Number of subjects included in analysis	1596
Analysis specification	Pre-specified
Analysis type	superiority ^[35]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	2.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.19
upper limit	2.62

Notes:

[35] - Superiority was concluded if the lower limit of the confidence interval of the day 50 vaccine group GMT ratios for at least 2 homologous strains was >1.5.

Statistical analysis title	GMT Ratio (B strain)
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1596
Analysis specification	Pre-specified
Analysis type	superiority ^[36]
Parameter estimate	GMT Ratio (B strain)
Point estimate	3.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.73
upper limit	3.47

Notes:

[36] - Superiority was concluded if the lower limit of the confidence interval of the day 50 vaccine group GMT ratios for at least 2 homologous strains was >1.5.

Secondary: Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4 Fold Increase in HI Titers Against Homologous Strains (6 to <72 Months)-FAS

End point title	Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4 Fold Increase in HI Titers Against Homologous Strains (6 to <72 Months)-FAS
-----------------	--

End point description:

The superiority of HI antibody responses, in subjects 6 to <24 months of age, of aTIV compared to TIV and comparator TIV assessed in terms of number of subjects achieving seroconversion ≥4 fold increase in HI titers at three weeks after last vaccination against the three homologous vaccine strains.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 50

End point values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	747	839	849	
Units: Percentage of Subjects				
number (confidence interval 95%)				

H1N1 (N=745, 849, 839)	92.8 (90.7 to 94.5)	83.7 (81 to 86.1)	78.8 (75.9 to 81.5)	
H3N2	96.4 (94.8 to 97.6)	92.3 (90.2 to 94)	89.8 (87.5 to 91.7)	
B strain	97.5 (96.1 to 98.5)	86.4 (83.9 to 88.7)	84.5 (81.8 to 86.8)	

Statistical analyses

Statistical analysis title	Group difference (H1N1 strain)
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1586
Analysis specification	Pre-specified
Analysis type	superiority ^[37]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	9.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.3
upper limit	12.4

Notes:

[37] - Superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference, for at least 2 homologous strains, was >10%.

Statistical analysis title	Group difference (H3N2 strain)
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1586
Analysis specification	Pre-specified
Analysis type	superiority ^[38]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	3.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.8
upper limit	5.9

Notes:

[38] - Superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference, for at least 2 homologous strains, was >10%.

Statistical analysis title	Group difference (B strain)
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1586
Analysis specification	Pre-specified
Analysis type	superiority ^[39]
Parameter estimate	Group difference (B strain)
Point estimate	10.7

Confidence interval	
level	95 %
sides	2-sided
lower limit	8.1
upper limit	13.3

Notes:

[39] - Superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference,for at least 2 homologous strains, was >10%.

Statistical analysis title	Group difference (H1N1 strain)
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1596
Analysis specification	Pre-specified
Analysis type	superiority ^[40]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	14.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	11.1
upper limit	17.7

Notes:

[40] - Superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference,for at least 2 homologous strains, was >10%.

Statistical analysis title	Group difference (H3N2 strain)
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1596
Analysis specification	Pre-specified
Analysis type	superiority ^[41]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	6.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.5
upper limit	9.1

Notes:

[41] - Superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference,for at least 2 homologous strains, was >10%.

Statistical analysis title	Group difference (B strain)
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1596
Analysis specification	Pre-specified
Analysis type	superiority ^[42]
Parameter estimate	Group difference (B strain)
Point estimate	10.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.3
upper limit	13.4

Notes:

[42] - Superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference, for at least 2 homologous strains, was >10%.

Secondary: The HI GMTs Against Homologous Strains, by Vaccine Group

End point title	The HI GMTs Against Homologous Strains, by Vaccine Group
-----------------	--

End point description:

The HI antibody titers against the three homologous strains following vaccination with either aTIV, licensed comparator or TIV, at three weeks and at six months after vaccination are reported as GMTs.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1, Day 29, Day 50, Day 209

End point values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	715	822	820	
Units: Titers				
geometric mean (confidence interval 95%)				
H1N1 - Day 1 (N=714,822,820)	28 (24 to 32)	24 (20 to 27)	27 (23 to 31)	
H1N1 - Day 29	647 (562 to 745)	159 (139 to 182)	170 (148 to 194)	
H1N1 - Day 50 (N=714,822,820)	1507 (1358 to 1673)	635 (575 to 702)	475 (429 to 525)	
H1N1 - Day 209 (N=715,822,819)	276 (246 to 311)	97 (87 to 109)	107 (96 to 120)	
H3N2 - Day 1	42 (36 to 48)	43 (37 to 49)	43 (38 to 50)	
H3N2 - Day 29	1087 (1004 to 1176)	558 (517 to 602)	453 (420 to 490)	
H3N2 - Day 50	1920 (1799 to 2050)	1013 (952 to 1079)	810 (760 to 862)	
H3N2 - Day 209	462 (423 to 505)	277 (254 to 301)	242 (222 to 263)	
B - Day 1	10 (9.29 to 11)	10 (9.57 to 11)	10 (9.34 to 11)	
B - Day 29	119 (106 to 134)	58 (52 to 65)	61 (54 to 68)	
B - Day 50	488 (447 to 532)	166 (153 to 180)	159 (146 to 173)	
B- Day 209	125 (114 to 136)	57 (53 to 62)	61 (56 to 66)	

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Ratio (GMR) of Post- Versus Pre-vaccination HI Titers Against Homologous Strains

End point title	Geometric Mean Ratio (GMR) of Post- Versus Pre-vaccination HI Titers Against Homologous Strains
-----------------	---

End point description:

The GMR of post-vaccination versus pre-vaccination HI titers against homologous strains, three weeks (day 29/day 1; day 50/day 1) and six months (day 209/day 1) after vaccination with either aTIV, licensed comparator or TIV.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 29, Day 50, Day 209

End point values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	715	822	820	
Units: Ratios				
geometric mean (confidence interval 95%)				
H1N1, Day 29:Day 1 (N=714,822,820)	27 (23 to 31)	6.81 (5.94 to 7.81)	7.13 (6.22 to 8.18)	
H1N1, Day 50:Day 1 (N=713,822,820)	58 (51 to 67)	27 (24 to 31)	19 (17 to 21)	
H1N1, Day 209:Day 1 (N=714,822,819)	11 (9.79 to 13)	4.15 (3.68 to 4.69)	4.37 (3.87 to 4.94)	
H3N2, Day 29:Day 1	29 (26 to 32)	15 (14 to 16)	12 (11 to 13)	
H3N2, Day 50:Day 1 (N=715,822,820)	48 (43 to 54)	25 (23 to 28)	20 (18 to 22)	
H3N2, Day 209:Day 1	12 (10 to 13)	6.93 (6.14 to 7.83)	6.02 (5.33 to 6.81)	
B strain, Day 29:Day 1	12 (11 to 14)	6.18 (5.49 to 6.95)	6.38 (5.66 to 7.18)	
B strain, Day 50:Day 1	49 (45 to 54)	17 (15 to 18)	16 (15 to 18)	
B strain, Day 209:Day 1	13 (12 to 14)	5.76 (5.26 to 6.3)	6.15 (5.62 to 6.73)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With HI Titers ≥ 40 Against Homologous Strains, by Vaccine Group

End point title	Percentage of Subjects With HI Titers ≥ 40 Against Homologous Strains, by Vaccine Group
-----------------	--

End point description:

The percentage of subjects demonstrating HI titers ≥ 40 , against homologous strains, at three weeks and six months after vaccination with aTIV or licensed comparator or TIV.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1, Day 29, Day 50, Day 209

End point values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	715	822	820	
Units: Ratios				
geometric mean (confidence interval 95%)				
H1N1, Day 1 (N=714,822,820)	40.6 (37 to 44.3)	33.1 (29.9 to 36.4)	36.3 (33 to 39.7)	
H1N1, Day 29	89.8 (87.3 to 91.9)	55 (51.5 to 58.4)	57.9 (54.5 to 61.3)	
H1N1, Day 50 (N=714,822,820)	99.3 (98.4 to 99.8)	91.1 (89 to 93)	88.2 (85.8 to 90.3)	
H1N1, Day 209 (N=715, 822,819)	88.8 (86.3 to 91)	59.5 (56 to 62.9)	63.2 (59.8 to 66.6)	
H3N2, Day 1	52.6 (48.9 to 56.3)	45.5 (42.1 to 49)	44.6 (41.2 to 48.1)	
H3N2, Day 29	98.9 (97.8 to 99.5)	95.9 (94.3 to 97.1)	93.5 (91.6 to 95.1)	
H3N2, Day 50	99.7 (99 to 100)	99.5 (98.8 to 99.9)	99.4 (98.6 to 99.8)	
H3N2, Day 209	99.3 (98.4 to 99.8)	94.3 (92.5 to 95.8)	88.4 (86 to 90.5)	
B strain, Day 1	22.1 (19.1 to 25.3)	21.1 (18.3 to 24)	20.5 (17.8 to 23.4)	
B strain, Day 29	69 (65.4 to 72.3)	48.2 (44.7 to 51.7)	45.6 (42.2 to 49.1)	
B strain, Day 50	98.9 (97.8 to 99.5)	89.1 (86.7 to 91.1)	87 (84.5 to 89.2)	
B strain, Day 209	93.4 (91.4 to 95.1)	67.9 (64.6 to 71.1)	67 (63.6 to 70.2)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving Seroconversion or ≥ 4 Fold Increase in HI Titers, Against Homologous Strains

End point title	Percentage of Subjects Achieving Seroconversion or ≥ 4 Fold Increase in HI Titers, Against Homologous Strains
End point description: The percentage of subjects achieving seroconversion ≥ 4 fold increase in HI titers from baseline, against homologous strains, at three weeks and six months after vaccination with ATIV or licensed comparator or TIV.	
End point type	Secondary
End point timeframe: Day 29, Day 50, Day 209	

End point values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	715	822	820	
Units: Percentage of Subjects				
number (confidence interval 95%)				
H1N1, Day 29 (N=714,822,820)	83.6 (80.7 to 86.3)	48.5 (45.1 to 52)	51.5 (48 to 54.9)	
H1N1, Day 50 (N=713,822,820)	92.6 (90.4 to 94.4)	83.9 (81.3 to 86.4)	79 (76.1 to 81.8)	
H1N1, Day 209 (N=714,822,819)	71.7 (68.3 to 75)	39.5 (36.2 to 43)	41.9 (38.5 to 45.3)	
H3N2, Day 29	95.8 (94.1 to 97.2)	90.3 (88 to 92.2)	86.7 (84.2 to 89)	
H3N2, Day 50	96.5 (94.9 to 97.7)	92.1 (90 to 93.8)	90 (87.7 to 92)	
H3N2, Day 209	77.6 (74.4 to 80.6)	62.5 (59.1 to 65.9)	55.6 (52.1 to 59.1)	
B strain, Day 29	68.4 (64.8 to 71.8)	47 (43.5 to 50.4)	44 (40.6 to 47.5)	
B strain, Day 50	97.6 (96.2 to 98.6)	86.6 (84.1 to 88.9)	85 (82.4 to 87.4)	
B strain, Day 209	87.3 (84.6 to 89.6)	59.7 (56.3 to 63.1)	61.5 (58 to 64.8)	

Statistical analyses

No statistical analyses for this end point

Secondary: Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains, Subjects at Risk/Not at Risk, by Age Subgroup

End point title	Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains, Subjects at Risk/Not at Risk, by Age Subgroup
-----------------	---

End point description:

The non-inferiority of Hemagglutination Inhibition (HI) antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains, in subjects with a defined set of underlying medical conditions (at risk) and healthy subjects (not at risk), by age sub group.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 50

End point values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)	aTIV (6 to <36 Months)
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	660	722	739	425
Units: Titers				
geometric mean (confidence interval 95%)				

H1N1nonrisk(N=659,722,739,425,612,623,234,110,116)	1516 (1358 to 1692)	566 (509 to 628)	431 (388 to 478)	1341 (1165 to 1544)
H3N2nonrisk(N=660,722,739,425,612,623,235,110,116)	1897 (1772 to 2030)	1014 (950 to 1082)	804 (754 to 857)	1863 (1711 to 2028)
B nonrisk(N=660,722,739,425,612,623,234,110,116)	492 (450 to 539)	162 (148 to 176)	157 (144 to 170)	559 (498 to 627)
H1N1 at risk(N=22,35,26,12,23,19,10,12,7)	1706 (990 to 2939)	772 (502 to 1185)	631 (383 to 1041)	1414 (658 to 3040)
H3N2 at risk(N=22,35,26,12,23,19,10,12,7)	2306 (1665 to 3194)	941 (727 to 1220)	709 (526 to 955)	2323 (1407 to 3835)
B at risk(N=22,35,26,12,23,19,10,12,7)	495 (307 to 797)	143 (98 to 209)	179 (116 to 278)	694 (367 to 1316)

End point values	Comparator TIV (6 to <36 Months)	TIV (6 to <36 Months)	aTIV (36 to <72 Months)	TIV (36 to <72 Months)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	612	623	235	116
Units: Titers				
geometric mean (confidence interval 95%)				
H1N1nonrisk(N=659,722,739,425,612,623,234,110,116)	478 (425 to 537)	366 (326 to 411)	2111 (1840 to 2423)	879 (723 to 1068)
H3N2nonrisk(N=660,722,739,425,612,623,235,110,116)	912 (849 to 979)	695 (648 to 746)	2311 (2080 to 2568)	1497 (1289 to 1739)
B nonrisk(N=660,722,739,425,612,623,234,110,116)	149 (136 to 164)	141 (128 to 155)	431 (380 to 488)	254 (212 to 304)
H1N1 at risk(N=22,35,26,12,23,19,10,12,7)	603 (350 to 1040)	519 (283 to 950)	2187 (956 to 5002)	1030 (383 to 2767)
H3N2 at risk(N=22,35,26,12,23,19,10,12,7)	794 (552 to 1140)	665 (447 to 988)	2319 (1622 to 3315)	826 (538 to 1267)
B at risk(N=22,35,26,12,23,19,10,12,7)	125 (79 to 199)	132 (79 to 220)	365 (184 to 724)	312 (131 to 743)

End point values	Comparator TIV (36 to <72 Months)			
Subject group type	Subject analysis set			
Number of subjects analysed	110			
Units: Titers				
geometric mean (confidence interval 95%)				
H1N1nonrisk(N=659,722,739,425,612,623,234,110,116)	1365 (1117 to 1668)			
H3N2nonrisk(N=660,722,739,425,612,623,235,110,116)	1526 (1309 to 1780)			
B nonrisk(N=660,722,739,425,612,623,234,110,116)	226 (188 to 272)			
H1N1 at risk(N=22,35,26,12,23,19,10,12,7)	1241 (583 to 2641)			
H3N2 at risk(N=22,35,26,12,23,19,10,12,7)	1306 (940 to 1815)			
B at risk(N=22,35,26,12,23,19,10,12,7)	200 (108 to 372)			

Statistical analyses

Statistical analysis title	GMT Ratio (H1N1 strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1382
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[43]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	2.68
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.3
upper limit	3.12

Notes:

[43] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1382
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[44]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	1.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.7
upper limit	2.05

Notes:

[44] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1382
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[45]
Parameter estimate	GMT Ratio (B strain)
Point estimate	3.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.68
upper limit	3.44

Notes:

[45] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1382
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[46]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	2.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.11
upper limit	4.42

Notes:

[46] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1382
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[47]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	2.45
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.61
upper limit	3.72

Notes:

[47] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1399
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[48]
Parameter estimate	GMT Ratio (B strain)
Point estimate	3.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.88
upper limit	6.34

Notes:

[48] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- No Risk
-----------------------------------	----------------------------------

Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1399
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[49]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	3.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.03
upper limit	4.1

Notes:

[49] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1399
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[50]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	2.36
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.15
upper limit	2.59

Notes:

[50] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- No Risk
Comparison groups	TIV (6 to <72 Months) v aTIV (6 to <72 Months)
Number of subjects included in analysis	1399
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[51]
Parameter estimate	GMT Ratio (B strain)
Point estimate	3.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.78
upper limit	3.56

Notes:

[51] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)

Number of subjects included in analysis	1399
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[52]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	2.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.28
upper limit	5.68

Notes:

[52] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1399
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[53]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	3.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.09
upper limit	5.06

Notes:

[53] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1399
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[54]
Parameter estimate	GMT Ratio (B strain)
Point estimate	2.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.44
upper limit	5.3

Notes:

[54] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)

Number of subjects included in analysis	1037
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[55]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	2.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.34
upper limit	3.37

Notes:

[55] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)
Number of subjects included in analysis	1037
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[56]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	2.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.83
upper limit	2.28

Notes:

[56] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)
Number of subjects included in analysis	1037
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[57]
Parameter estimate	GMT Ratio (B strain)
Point estimate	3.74
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.22
upper limit	4.34

Notes:

[57] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)

Number of subjects included in analysis	1037
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[58]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	2.34
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.92
upper limit	6

Notes:

[58] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)
Number of subjects included in analysis	1037
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[59]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	2.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.57
upper limit	5.45

Notes:

[59] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)
Number of subjects included in analysis	1037
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[60]
Parameter estimate	GMT Ratio (B strain)
Point estimate	5.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.52
upper limit	12

Notes:

[60] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)

Number of subjects included in analysis	1048
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[61]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	3.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.05
upper limit	4.39

Notes:

[61] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1048
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[62]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	2.68
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.4
upper limit	2.99

Notes:

[62] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1048
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[63]
Parameter estimate	GMT Ratio (B strain)
Point estimate	3.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.42
upper limit	4.61

Notes:

[63] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)

Number of subjects included in analysis	1048
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[64]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	2.72
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.02
upper limit	7.31

Notes:

[64] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1048
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[65]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	3.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.85
upper limit	6.62

Notes:

[65] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1048
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[66]
Parameter estimate	GMT Ratio (B strain)
Point estimate	5.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.32
upper limit	12

Notes:

[66] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)

Number of subjects included in analysis	345
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[67]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	1.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.21
upper limit	1.97

Notes:

[67] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)
Number of subjects included in analysis	345
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[68]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	1.51
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.26
upper limit	1.82

Notes:

[68] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)
Number of subjects included in analysis	345
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[69]
Parameter estimate	GMT Ratio (B strain)
Point estimate	1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.52
upper limit	2.38

Notes:

[69] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)

Number of subjects included in analysis	345
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[70]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	1.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.57
upper limit	5.4

Notes:

[70] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)
Number of subjects included in analysis	345
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[71]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	1.78
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.09
upper limit	2.89

Notes:

[71] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)
Number of subjects included in analysis	345
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[72]
Parameter estimate	GMT Ratio (B strain)
Point estimate	1.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	4.54

Notes:

[72] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)

Number of subjects included in analysis	351
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[73]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	2.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.89
upper limit	3.05

Notes:

[73] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)
Number of subjects included in analysis	351
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[74]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	1.54
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.29
upper limit	1.85

Notes:

[74] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)
Number of subjects included in analysis	351
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[75]
Parameter estimate	GMT Ratio (B strain)
Point estimate	1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.36
upper limit	2.11

Notes:

[75] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)

Number of subjects included in analysis	351
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[76]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	2.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.58
upper limit	7.71

Notes:

[76] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)
Number of subjects included in analysis	351
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[77]
Parameter estimate	GMT Ratio (B strain)
Point estimate	1.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.37
upper limit	3.67

Notes:

[77] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)
Number of subjects included in analysis	351
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[78]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	2.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.61
upper limit	4.89

Notes:

[78] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Secondary: Comparison of Antibody Responses of aTIV Versus Comparator TIV and TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains in Subjects at Risk/Not at Risk, by Age Subgroup

End point title	Comparison of Antibody Responses of aTIV Versus Comparator TIV and TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains in Subjects at Risk/Not at Risk, by Age
-----------------	---

Subgroup	
End point description:	
The non-inferiority of HI antibody responses of aTIV to that of the licensed comparator TIV and to investigational TIV was assessed in terms of percentage of subjects achieving seroconversion or ≥ 4 -fold increase in HI titers at three weeks after last vaccination against the three homologous vaccine strains in subjects with a defined set of underlying medical conditions (at risk) and in healthy subjects (not at risk) , by age sub group.	
End point type	Secondary
End point timeframe:	
Day 50	

End point values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)	aTIV (6 to <36 Months)
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	660	722	739	425
Units: Percentage of Subjects				
number (confidence interval 95%)				
H1N1 norisk(N=658,722,739,425,612,623,23)	93 (91 to 95)	85 (82 to 87)	79 (76 to 82)	95 (92 to 97)
H3N2 norisk(N=660,722,739,425,612,623,23)	97 (95 to 98)	93 (91 to 94)	90 (87 to 92)	98 (96 to 99)
B norisk(N=660,722,739,425,612,623,23)	98 (96 to 99)	86 (83 to 88)	84 (82 to 87)	98 (96 to 99)
H1N1 at risk (N=22,35,26,12,23,19,10,12,7)	82 (60 to 95)	83 (66 to 93)	85 (65 to 96)	92 (62 to 100)
H3N2 at risk(N=22,35,26,12,23,19,10,12,7)	86 (65 to 97)	86 (70 to 95)	81 (61 to 93)	83 (52 to 98)
B at risk(N=22,35,26,12,23,19,10,12,7)	100 (85 to 100)	86 (70 to 95)	88 (70 to 98)	100 (74 to 100)

End point values	Comparator TIV (6 to <36 Months)	TIV (6 to <36 Months)	aTIV (36 to <72 Months)	TIV (36 to <72 Months)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	612	623	235	116
Units: Percentage of Subjects				
number (confidence interval 95%)				
H1N1 norisk(N=658,722,739,425,612,623,23)	84 (81 to 87)	78 (75 to 82)	91 (86 to 94)	83 (75 to 89)
H3N2 norisk(N=660,722,739,425,612,623,23)	93 (91 to 95)	90 (88 to 93)	94 (91 to 97)	86 (79 to 92)
B norisk(N=660,722,739,425,612,623,23)	85 (82 to 88)	83 (79 to 86)	98 (95 to 99)	94 (88 to 98)
H1N1 at risk (N=22,35,26,12,23,19,10,12,7)	87 (66 to 97)	89 (67 to 99)	70 (35 to 93)	71 (29 to 96)
H3N2 at risk(N=22,35,26,12,23,19,10,12,7)	78 (56 to 93)	74 (49 to 91)	90 (55 to 100)	100 (59 to 100)
B at risk(N=22,35,26,12,23,19,10,12,7)	91 (72 to 99)	84 (60 to 97)	100 (69 to 100)	100 (59 to 100)

End point values	Comparator TIV (36 to <72 Months)			
Subject group type	Subject analysis set			
Number of subjects analysed	110			
Units: Percentage of Subjects				
number (confidence interval 95%)				
H1N1 norisk(N=658,722,739,425,612,623,23)	88 (81 to 94)			
H3N2 norisk(N=660,722,739,425,612,623,23)	90 (83 to 95)			
B norisk(N=660,722,739,425,612,623,23)	90 (83 to 95)			
H1N1 at risk (N=22,35,26,12,23,19,10,12,7)	75 (43 to 95)			
H3N2 at risk(N=22,35,26,12,23,19,10,12,7)	100 (74 to 100)			
B at risk(N=22,35,26,12,23,19,10,12,7)	75 (43 to 95)			

Statistical analyses

Statistical analysis title	Group difference (H1N1 strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1382
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[79]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	9
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.4
upper limit	12

Notes:

[79] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1382
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[80]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	4

Confidence interval	
level	95 %
sides	2-sided
lower limit	1.8
upper limit	6.6

Notes:

[80] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1382
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[81]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24
upper limit	18.7

Notes:

[81] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1382
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[82]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21.2
upper limit	18.9

Notes:

[82] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1382
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[83]
Parameter estimate	Group difference (B strain)
Point estimate	14
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.6
upper limit	29.5

Notes:

[83] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was $> -10\%$.

Statistical analysis title	Group difference (H1N1 strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1399
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[84]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	14
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.7
upper limit	17.7

Notes:

[84] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was $> -10\%$.

Statistical analysis title	Group difference (H3N2 strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1399
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[85]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	7
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.6
upper limit	9.8

Notes:

[85] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was $> -10\%$.

Statistical analysis title	Group difference (B strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1399
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[86]
Parameter estimate	Group difference (B strain)
Point estimate	13
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.7
upper limit	16.4

Notes:

[86] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was $> -10\%$.

Statistical analysis title	Group difference (H3N2 strain)- Risk
-----------------------------------	--------------------------------------

Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1399
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[87]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.5
upper limit	27.3

Notes:

[87] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1399
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[88]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	-3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.1
upper limit	19.2

Notes:

[88] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1399
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[89]
Parameter estimate	Group difference (B strain)
Point estimate	12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.4
upper limit	29.2

Notes:

[89] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)

Number of subjects included in analysis	1037
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[90]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	11
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.2
upper limit	14.5

Notes:

[90] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)
Number of subjects included in analysis	1037
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[91]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	5
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.6
upper limit	7.5

Notes:

[91] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)
Number of subjects included in analysis	1037
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[92]
Parameter estimate	Group difference (B strain)
Point estimate	13
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.5
upper limit	15.8

Notes:

[92] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)

Number of subjects included in analysis	1037
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[93]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.7
upper limit	26.3

Notes:

[93] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)
Number of subjects included in analysis	1037
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[94]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.9
upper limit	30.3

Notes:

[94] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)
Number of subjects included in analysis	1037
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[95]
Parameter estimate	Group difference (B strain)
Point estimate	9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.9
upper limit	27.1

Notes:

[95] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)

Number of subjects included in analysis	1048
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[96]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	16
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.4
upper limit	20.2

Notes:

[96] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1048
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[97]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	8
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.1
upper limit	10.5

Notes:

[97] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1048
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[98]
Parameter estimate	Group difference (B strain)
Point estimate	15
Confidence interval	
level	95 %
sides	2-sided
lower limit	12
upper limit	18.6

Notes:

[98] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)

Number of subjects included in analysis	1048
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[99]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.1
upper limit	25.5

Notes:

[99] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1048
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[100]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	10
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.5
upper limit	37.2

Notes:

[100] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1048
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[101]
Parameter estimate	Group difference (B strain)
Point estimate	16
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.7
upper limit	38

Notes:

[101] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)

Number of subjects included in analysis	345
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[102]
Parameter estimate	Group difference (B strain)
Point estimate	2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.2
upper limit	10.4

Notes:

[102] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)
Number of subjects included in analysis	345
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[103]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	11.9

Notes:

[103] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)
Number of subjects included in analysis	345
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[104]
Parameter estimate	Group difference (B strain)
Point estimate	8
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.9
upper limit	15.1

Notes:

[104] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)

Number of subjects included in analysis	345
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[105]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	-5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-42.4
upper limit	32

Notes:

[105] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)
Number of subjects included in analysis	345
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[106]
Parameter estimate	Group difference (B strain)
Point estimate	25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.1
upper limit	53.9

Notes:

[106] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)
Number of subjects included in analysis	345
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[107]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	-10
Confidence interval	
level	95 %
sides	2-sided
lower limit	-41.2
upper limit	16.6

Notes:

[107] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)

Number of subjects included in analysis	351
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[108]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	8
Confidence interval	
level	95 %
sides	2-sided
lower limit	1
upper limit	16.4

Notes:

[108] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)
Number of subjects included in analysis	351
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[109]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	8
Confidence interval	
level	95 %
sides	2-sided
lower limit	2
upper limit	16.1

Notes:

[109] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)
Number of subjects included in analysis	351
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[110]
Parameter estimate	Group difference (B strain)
Point estimate	4
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	10

Notes:

[110] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)

Number of subjects included in analysis	351
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[111]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-42.1
upper limit	43

Notes:

[111] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)
Number of subjects included in analysis	351
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[112]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	-10
Confidence interval	
level	95 %
sides	2-sided
lower limit	-41.5
upper limit	28.7

Notes:

[112] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)
Number of subjects included in analysis	351
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[113]
Parameter estimate	Group difference (B strain)
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-29
upper limit	36.8

Notes:

[113] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Secondary: Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains in Subjects at Risk/Not at Risk, by Age Sub Group-FAS

End point title	Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains in Subjects at Risk/Not at Risk, by Age
-----------------	--

End point description:

The superiority of HI antibody responses of ATIV compared to TIV and comparator TIV assessed in terms of percentage of subjects achieving seroconversion or ≥ 4 -fold increase in HI Titer at three weeks after last vaccination against the three homologous vaccine strains in subjects with a defined set of underlying medical conditions (at risk) and healthy subjects (not at risk), by age sub group.

End point type

Secondary

End point timeframe:

Day 50

End point values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)	aTIV (6 to <36 Months)
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	719	799	814	459
Units: Percentage of Subjects				
number (confidence interval 95%)				
H1N1 norisk(N=717,799,814,459,673,688,25)	93 (91 to 95)	84 (81 to 86)	79 (76 to 81)	95 (92 to 96)
H3N2 norisk(N=719,799,814,459,673,688,26)	97 (95 to 98)	93 (91 to 94)	90 (88 to 92)	98 (96 to 99)
B norisk(N=719,799,814,459,673,688,26)	97 (96 to 99)	86 (84 to 89)	84 (82 to 87)	98 (96 to 99)
H1N1 at risk(N=28,40,35,17,26,26,11,14,9)	79 (59 to 92)	83 (67 to 93)	83 (66 to 93)	82 (57 to 96)
H3N2 at risk(N=28,40,35,17,26,26,11,14,9)	89 (72 to 98)	85 (70 to 94)	83 (66 to 93)	88 (64 to 99)
B at risk(N=28,40,35,17,26,26,11,14,9)	96 (82 to 100)	88 (73 to 96)	89 (73 to 97)	94 (71 to 100)

End point values	Comparator TIV (6 to <36 Months)	TIV (6 to <36 Months)	aTIV (36 to <72 Months)	TIV (36 to <72 Months)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	673	688	260	126
Units: Percentage of Subjects				
number (confidence interval 95%)				
H1N1 norisk(N=717,799,814,459,673,688,25)	83 (80 to 86)	78 (75 to 81)	91 (87 to 94)	81 (73 to 87)
H3N2 norisk(N=719,799,814,459,673,688,26)	93 (91 to 95)	91 (88 to 93)	95 (91 to 97)	87 (79 to 92)
B norisk(N=719,799,814,459,673,688,26)	85 (83 to 88)	83 (80 to 85)	97 (95 to 99)	94 (88 to 97)
H1N1 at risk(N=28,40,35,17,26,26,11,14,9)	85 (65 to 96)	85 (65 to 96)	73 (39 to 94)	78 (40 to 97)
H3N2 at risk(N=28,40,35,17,26,26,11,14,9)	77 (56 to 91)	77 (56 to 91)	91 (59 to 100)	100 (66 to 100)
B at risk(N=28,40,35,17,26,26,11,14,9)	92 (75 to 99)	85 (65 to 96)	100 (72 to 100)	100 (66 to 100)

End point values	Comparator TIV (36 to <72 Months)			
Subject group type	Subject analysis set			
Number of subjects analysed	126			
Units: Percentage of Subjects				
number (confidence interval 95%)				
H1N1 norisk(N=717,799,814,459,673,688,25)	89 (82 to 94)			
H3N2 norisk(N=719,799,814,459,673,688,26)	91 (85 to 96)			
B norisk(N=719,799,814,459,673,688,26)	91 (85 to 96)			
H1N1 at risk(N=28,40,35,17,26,26,11,14,9)	79 (49 to 95)			
H3N2 at risk(N=28,40,35,17,26,26,11,14,9)	100 (77 to 100)			
B at risk(N=28,40,35,17,26,26,11,14,9)	79 (49 to 95)			

Statistical analyses

Statistical analysis title	Group difference (H1N1 strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1518
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[114]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	10
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.4
upper limit	12.8

Notes:

[114] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1518
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[115]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	4
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.8
upper limit	6.4

Notes:

[115] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1518
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[116]
Parameter estimate	Group difference (B strain)
Point estimate	11
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.6
upper limit	13.9

Notes:

[116] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1518
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[117]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	-4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.7
upper limit	14.9

Notes:

[117] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1518
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[118]
Parameter estimate	Group difference (B strain)
Point estimate	9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.8
upper limit	23.4

Notes:

[118] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- Risk
-----------------------------------	--------------------------------------

Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1518
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[119]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.4
upper limit	20.7

Notes:

[119] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1533
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[120]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	15
Confidence interval	
level	95 %
sides	2-sided
lower limit	11.3
upper limit	18.1

Notes:

[120] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1533
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[121]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	7
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.2
upper limit	9.1

Notes:

[121] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)

Number of subjects included in analysis	1533
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[122]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	-4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-25.3
upper limit	15.4

Notes:

[122] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1533
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[123]
Parameter estimate	Group difference (B strain)
Point estimate	13
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.5
upper limit	16.1

Notes:

[123] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1533
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[124]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.7
upper limit	24.2

Notes:

[124] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)

Number of subjects included in analysis	1533
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[125]
Parameter estimate	Group difference (B strain)
Point estimate	8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.8
upper limit	23.2

Notes:

[125] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)
Number of subjects included in analysis	1132
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[126]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	12
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.2
upper limit	15.3

Notes:

[126] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)
Number of subjects included in analysis	1132
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[127]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	5
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.5
upper limit	7.4

Notes:

[127] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)

Number of subjects included in analysis	1132
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[128]
Parameter estimate	Group difference (B strain)
Point estimate	12
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.2
upper limit	15.3

Notes:

[128] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)
Number of subjects included in analysis	1132
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[129]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	-2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-28.5
upper limit	20.2

Notes:

[129] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)
Number of subjects included in analysis	1132
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[130]
Parameter estimate	Group difference (H3N2H1N1 strain)
Point estimate	11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.9
upper limit	33.5

Notes:

[130] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)

Number of subjects included in analysis	1132
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[131]
Parameter estimate	Group difference (B strain)
Point estimate	2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.7
upper limit	19.7

Notes:

[131] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1147
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[132]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	16
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.6
upper limit	20.1

Notes:

[132] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1147
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[133]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	7
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.6
upper limit	9.8

Notes:

[133] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)

Number of subjects included in analysis	1147
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[134]
Parameter estimate	Group difference (B strain)
Point estimate	15
Confidence interval	
level	95 %
sides	2-sided
lower limit	11.9
upper limit	18.3

Notes:

[134] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1147
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[135]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	-2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-28.5
upper limit	20.2

Notes:

[135] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1147
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[136]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.9
upper limit	33.5

Notes:

[136] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)

Number of subjects included in analysis	1147
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[137]
Parameter estimate	Group difference (B strain)
Point estimate	10
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14
upper limit	29.3

Notes:

[137] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)
Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[138]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.8
upper limit	9.5

Notes:

[138] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)
Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[139]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.8
upper limit	10

Notes:

[139] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)

Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[140]
Parameter estimate	Group difference (B strain)
Point estimate	6
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.5
upper limit	12.5

Notes:

[140] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)
Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[141]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	-6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-40.7
upper limit	27.9

Notes:

[141] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)
Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[142]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	-9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-38.4
upper limit	14.3

Notes:

[142] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)

Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[143]
Parameter estimate	Group difference (B strain)
Point estimate	21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.9
upper limit	48.1

Notes:

[143] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)
Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[144]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	10
Confidence interval	
level	95 %
sides	2-sided
lower limit	3
upper limit	18.5

Notes:

[144] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)
Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[145]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	8
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.2
upper limit	15.6

Notes:

[145] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)

Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[146]
Parameter estimate	Group difference (B strain)
Point estimate	4
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	9.6

Notes:

[146] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H1N1 strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)
Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[147]
Parameter estimate	Group difference (H1N1 strain)
Point estimate	-5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-41.7
upper limit	35

Notes:

[147] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (H3N2 strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)
Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[148]
Parameter estimate	Group difference (H3N2 strain)
Point estimate	-9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-38.6
upper limit	23.4

Notes:

[148] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Statistical analysis title	Group difference (B strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)

Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[149]
Parameter estimate	Group difference (B strain)
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.9
upper limit	31

Notes:

[149] - Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was > -10%.

Secondary: Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains, at Risk/Not at Risk, by Age Sub Group-FAS

End point title	Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains, at Risk/Not at Risk, by Age Sub Group-FAS
-----------------	---

End point description:

The superiority of HI antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains, in subjects with a defined set of underlying medical conditions (at risk) and in healthy subjects (not at risk), by age sub group.

End point type	Secondary
End point timeframe:	
Day 50	

End point values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)	aTIV (6 to <36 Months)
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	719	799	814	459
Units: Titers				
geometric mean (confidence interval 95%)				
H1N1 norisk(N=718,799,814,459,673,688,25)	1509 (1357 to 1677)	569 (515 to 629)	422 (382 to 466)	1336 (1166 to 1530)
H3N2 norisk(N=719,799,814,459,673,688,26)	1894 (1775 to 2022)	1015 (954 to 1080)	794 (747 to 844)	1851 (1705 to 2010)
B norisk(N=719,814,799,459,673,688,26)	484 (444 to 527)	164 (151 to 178)	155 (143 to 168)	545 (487 to 608)
H1N1 at risk(N=28,40,35,17,26,26,11,14,9)	1541 (948 to 2504)	830 (553 to 1244)	586 (380 to 905)	1277 (674 to 2418)
H3N2 at risk(N=28,40,35,17,26,26,11,14,9)	2361 (1743 to 3197)	960 (744 to 1237)	763 (582 to 1001)	2517 (1633 to 3881)
B at risk(N=28,40,35,17,26,26,11,14,9)	399 (254 to 628)	152 (104 to 222)	183 (122 to 274)	508 (274 to 939)

End point values	Comparator TIV (6 to <36 Months)	TIV (6 to <36 Months)	aTIV (36 to <72 Months)	TIV (36 to <72 Months)
------------------	----------------------------------	-----------------------	-------------------------	------------------------

	Months)			
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	673	688	260	126
Units: Titers				
geometric mean (confidence interval 95%)				
H1N1 norisk(N=718,799,814,459,673,688,25	474 (424 to 530)	365 (326 to 407)	2077 (1815 to 2376)	813 (670 to 986)
H3N2 norisk(N=719,799,814,459,673,688,26	905 (845 to 968)	686 (641 to 733)	2343 (2120 to 2589)	1475 (1278 to 1703)
B norisk(N=719,814,799,459,673,688,26	150 (137 to 164)	139 (127 to 152)	432 (383 to 487)	253 (212 to 300)
H1N1 at risk(N=28,40,35,17,26,26,11,14,9)	617 (370 to 1028)	483 (289 to 808)	1982 (929 to 4228)	1028 (445 to 2372)
H3N2 at risk(N=28,40,35,17,26,26,11,14,9)	820 (578 to 1164)	705 (496 to 1000)	2197 (1514 to 3187)	929 (616 to 1399)
B at risk(N=28,40,35,17,26,26,11,14,9)	140 (85 to 231)	147 (89 to 242)	319 (170 to 596)	241 (118 to 493)

End point values	Comparator TIV (36 to <72 Months)			
Subject group type	Subject analysis set			
Number of subjects analysed	126			
Units: Titers				
geometric mean (confidence interval 95%)				
H1N1 norisk(N=718,799,814,459,673,688,25	1413 (1165 to 1713)			
H3N2 norisk(N=719,799,814,459,673,688,26	1582 (1370 to 1826)			
B norisk(N=719,814,799,459,673,688,26	243 (205 to 289)			
H1N1 at risk(N=28,40,35,17,26,26,11,14,9)	1478 (756 to 2891)			
H3N2 at risk(N=28,40,35,17,26,26,11,14,9)	1286 (925 to 1788)			
B at risk(N=28,40,35,17,26,26,11,14,9)	197 (114 to 341)			

Statistical analyses

Statistical analysis title	GMT Ratio (H1N1 strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1518
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[150]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	2.29

Confidence interval	
level	95 %
sides	2-sided
lower limit	1.91
upper limit	2.76

Notes:

[150] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1518
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[151]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	1.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.35
upper limit	1.89

Notes:

[151] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1518
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[152]
Parameter estimate	GMT Ratio (B strain)
Point estimate	2.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.57
upper limit	3.31

Notes:

[152] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1518
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[153]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	1.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.6
upper limit	3.93

Notes:

[153] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1518
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[154]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	2.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.89
upper limit	4.61

Notes:

[154] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1518
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[155]
Parameter estimate	GMT Ratio (B strain)
Point estimate	2.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.34
upper limit	4.67

Notes:

[155] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1533
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[156]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	3.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.77
upper limit	4.01

Notes:

[156] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- No Risk
-----------------------------------	----------------------------------

Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1533
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[157]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	2.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.75
upper limit	2.45

Notes:

[157] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- No Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1533
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[158]
Parameter estimate	GMT Ratio (B strain)
Point estimate	3.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.72
upper limit	3.49

Notes:

[158] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1533
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[159]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	1.71
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.65
upper limit	4.5

Notes:

[159] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)

Number of subjects included in analysis	1533
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[160]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	3.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.38
upper limit	7.51

Notes:

[160] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- Risk
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1533
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[161]
Parameter estimate	GMT Ratio (B strain)
Point estimate	2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.1
upper limit	3.98

Notes:

[161] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- No Risk
Comparison groups	Comparator TIV (6 to <36 Months) v aTIV (6 to <36 Months)
Number of subjects included in analysis	1132
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[162]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	2.59
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.1
upper limit	3.21

Notes:

[162] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)

Number of subjects included in analysis	1132
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[163]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	2.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.71
upper limit	2.52

Notes:

[163] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)
Number of subjects included in analysis	1132
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[164]
Parameter estimate	GMT Ratio (B strain)
Point estimate	3.73
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.22
upper limit	4.33

Notes:

[164] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)
Number of subjects included in analysis	1132
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[165]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.45
upper limit	4.4

Notes:

[165] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)

Number of subjects included in analysis	1132
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[166]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	2.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.94
upper limit	8.66

Notes:

[166] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v Comparator TIV (6 to <36 Months)
Number of subjects included in analysis	1132
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[167]
Parameter estimate	GMT Ratio (B strain)
Point estimate	1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.45
upper limit	4.4

Notes:

[167] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1147
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[168]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	3.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.97
upper limit	4.54

Notes:

[168] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)

Number of subjects included in analysis	1147
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[169]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	2.78
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.29
upper limit	3.37

Notes:

[169] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- No Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1147
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[170]
Parameter estimate	GMT Ratio (B strain)
Point estimate	4.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.46
upper limit	4.65

Notes:

[170] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1147
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[171]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.45
upper limit	4.4

Notes:

[171] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)

Number of subjects included in analysis	1147
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[172]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	4.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.43
upper limit	13

Notes:

[172] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- Risk
Comparison groups	aTIV (6 to <36 Months) v TIV (6 to <36 Months)
Number of subjects included in analysis	1147
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[173]
Parameter estimate	GMT Ratio (B strain)
Point estimate	3.69
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.67
upper limit	8.15

Notes:

[173] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)
Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[174]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	1.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.89
upper limit	2.04

Notes:

[174] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)

Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[175]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	1.59
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.14
upper limit	2.22

Notes:

[175] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)
Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[176]
Parameter estimate	GMT Ratio (B strain)
Point estimate	1.68
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.3
upper limit	2.15

Notes:

[176] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)
Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[177]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	1.73
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.29
upper limit	10

Notes:

[177] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)

Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[178]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	1.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.33
upper limit	4.01

Notes:

[178] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v Comparator TIV (36 to <72 Months)
Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[179]
Parameter estimate	GMT Ratio (B strain)
Point estimate	1.45
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.53
upper limit	3.94

Notes:

[179] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)
Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[180]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	2.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.48
upper limit	3.39

Notes:

[180] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)

Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[181]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	1.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.26
upper limit	2.46

Notes:

[181] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- No Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)
Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[182]
Parameter estimate	GMT Ratio (B strain)
Point estimate	1.59
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.24
upper limit	2.04

Notes:

[182] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H1N1 strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)
Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[183]
Parameter estimate	GMT Ratio (H1N1 strain)
Point estimate	2.48
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.34
upper limit	18

Notes:

[183] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (H3N2 strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)

Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[184]
Parameter estimate	GMT Ratio (H3N2 strain)
Point estimate	1.98
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.49
upper limit	7.92

Notes:

[184] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Statistical analysis title	GMT Ratio (B strain)- Risk
Comparison groups	aTIV (36 to <72 Months) v TIV (36 to <72 Months)
Number of subjects included in analysis	386
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[185]
Parameter estimate	GMT Ratio (B strain)
Point estimate	0.71
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.23
upper limit	2.16

Notes:

[185] - Noninferiority was concluded if the lower limit of the 2-sided 95% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.

Secondary: The HI GMTs Against Heterologous Strains, by Vaccine Group (6 to <72 Months Age Group)

End point title	The HI GMTs Against Heterologous Strains, by Vaccine Group (6 to <72 Months Age Group)
End point description:	
The HI antibody titers against the heterologous strains following vaccination with either aTIV, licensed comparator or TIV, at three weeks and at six months after vaccination are reported as GMTs.	
End point type	Secondary
End point timeframe:	
Day 1, Day 50, Day 209	

End point values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	380	445	431	
Units: Titers				
number (confidence interval 95%)				
H1N1/Jersey - Day 1 (N=380,445,430)	10 (9.37 to 11)	9.75 (8.85 to 11)	10 (9.07 to 11)	
H1N1/Jersey - Day 50	51 (45 to 58)	29 (26 to 33)	31 (27 to 36)	

H1N1/Jersey - Day 209	21 (19 to 23)	17 (16 to 19)	18 (16 to 20)	
H3N2/Uruguay - Day 1 (N=380,445,430)	17 (15 to 20)	18 (16 to 20)	17 (15 to 19)	
H3N2/Uruguay - Day 50	184 (165 to 206)	88 (79 to 98)	71 (63 to 79)	
H3N2/Uruguay- Day 209	42 (37 to 47)	31 (28 to 34)	27 (24 to 30)	
B strain - Day 1	5.98 (5.72 to 6.25)	5.8 (5.55 to 6.05)	5.85 (5.6 to 6.11)	
B strain - Day 50	99 (89 to 111)	34 (31 to 38)	35 (31 to 39)	
B strain Day 209	20 (18 to 22)	11 (9.86 to 12)	11 (9.94 to 12)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving Seroconversion or ≥ 4 Fold Increase in HI Titers, Against Heterologous Strains

End point title	Percentage of Subjects Achieving Seroconversion or ≥ 4 Fold Increase in HI Titers, Against Heterologous Strains
-----------------	--

End point description:

The percentage of subjects achieving seroconversion or ≥ 4 fold increase in HI titers from baseline, against heterologous strains, at three weeks and six months after last vaccination with aTIV or licensed comparator or TIV.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 50, Day 209

End point values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	380	445	431	
Units: Percentage of Subjects				
number (confidence interval 95%)				
H1N1/Jersey, Day 50 (N=380,445,430)	53.16 (48 to 58.26)	36.85 (32.36 to 41.52)	36.05 (31.5 to 40.78)	
H1N1/Jersey, Day 209 (N=380,445,430)	33.95 (29.2 to 38.95)	19.33 (15.76 to 23.31)	20.7 (16.96 to 24.84)	
H3N2/Uruguay, Day 50 (N=380,445,430)	91.84 (88.62 to 94.39)	60.9 (56.19 to 65.46)	53.26 (48.42 to 58.05)	
H3N2/Uruguay, Day 209 (N=380,445,430)	40.26 (35.29 to 45.39)	23.82 (19.94 to 28.06)	19.07 (15.46 to 23.11)	
B strain, Day 50	92.63 (89.53 to 95.05)	53.71 (48.95 to 58.41)	52.9 (48.07 to 57.69)	
B strain, Day 209	30 (25.43 to 34.88)	13.93 (10.85 to 17.5)	17.63 (14.15 to 21.57)	

Statistical analyses

Secondary: Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains, After One Vaccination

End point title	Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains, After One Vaccination
End point description:	To demonstrate the GMTs at three weeks after one dose of aTIV are statistically significantly higher to the corresponding response's of comparator TIV and TIV.
End point type	Secondary
End point timeframe:	Day 1, Day 29

End point values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	715	822	820	
Units: Percentage of Subjects				
geometric mean (confidence interval 95%)				
H1N1- Day 1 (N=714,822,820)	28 (24 to 32)	24 (20 to 27)	27 (23 to 31)	
H1N1- Day 29	647 (562 to 745)	159 (139 to 182)	170 (148 to 194)	
H3N2 - Day 1	42 (36 to 48)	43 (37 to 49)	43 (38 to 50)	
H3N2 - Day 29	1087 (1004 to 1176)	558 (517 to 602)	453 (420 to 490)	
B strain Day 1	10 (9.29 to 11)	10 (9.57 to 11)	10 (9.34 to 11)	
B strain Day 29	119 (106 to 134)	58 (52 to 65)	61 (54 to 68)	

Statistical analyses

Statistical analysis title	GMT ratio (H1N1 strain)
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1537
Analysis specification	Pre-specified
Analysis type	other ^[186]
Parameter estimate	GMT ratio (H1N1 strain)
Point estimate	4.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.34
upper limit	4.95

Notes:

[186] - GMTs were considered to be statistically significantly higher if the lower bound of the 95% confidence interval around the vaccine group ratio was >1.0.

Statistical analysis title	GMT ratio (H3N2 strain)
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1537
Analysis specification	Pre-specified
Analysis type	other ^[187]
Parameter estimate	GMT ratio (H3N2 strain)
Point estimate	1.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.74
upper limit	2.18

Notes:

[187] - GMTs were considered to be statistically significantly higher if the lower bound of the 95% confidence interval around the vaccine group ratio was >1.0.

Statistical analysis title	GMT ratio (B strain)
Comparison groups	aTIV (6 to <72 Months) v Comparator TIV (6 to <72 Months)
Number of subjects included in analysis	1537
Analysis specification	Pre-specified
Analysis type	other ^[188]
Parameter estimate	GMT ratio (B strain)
Point estimate	2.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.73
upper limit	2.39

Notes:

[188] - GMTs were considered to be statistically significantly higher if the lower bound of the 95% confidence interval around the vaccine group ratio was >1.0.

Statistical analysis title	GMT ratio (H1N1 strain)
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1535
Analysis specification	Pre-specified
Analysis type	other ^[189]
Parameter estimate	GMT ratio (H1N1 strain)
Point estimate	3.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.14
upper limit	4.64

Notes:

[189] - GMTs were considered to be statistically significantly higher if the lower bound of the 95% confidence interval around the vaccine group ratio was >1.0.

Statistical analysis title	GMT ratio (H3N2 strain)
-----------------------------------	-------------------------

Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1535
Analysis specification	Pre-specified
Analysis type	other ^[190]
Parameter estimate	GMT ratio (H3N2 strain)
Point estimate	2.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.15
upper limit	2.68

Notes:

[190] - GMTs were considered to be statistically significantly higher if the lower bound of the 95% confidence interval around the vaccine group ratio was >1.0.

Statistical analysis title	GMT ratio (B strain)
Comparison groups	aTIV (6 to <72 Months) v TIV (6 to <72 Months)
Number of subjects included in analysis	1535
Analysis specification	Pre-specified
Analysis type	other ^[191]
Parameter estimate	GMT ratio (B strain)
Point estimate	1.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.65
upper limit	2.29

Notes:

[191] - GMTs were considered to be statistically significantly higher if the lower bound of the 95% confidence interval around the vaccine group ratio was >1.0.

Secondary: Number of Subjects Reporting Solicited Adverse Events After Vaccination

End point title	Number of Subjects Reporting Solicited Adverse Events After Vaccination
-----------------	---

End point description:

The number of subjects reporting any solicited local and systemic adverse events (AEs), following vaccination with aTIV or licensed comparator or TIV.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 through Day 7 after any vaccination

End point values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	3082	1453	1451	
Units: Percentage of Subjects				
Any local	1082	292	311	
Injection site	191	72	86	
ecchymosis(N=3075,1450,1446)				

Injection site erythema (N=3075,1450,1446)	312	109	101	
Injection site induration (N=3075,1450,1446)	258	62	67	
Injection site tenderness (N=1495,1025,1012)	152	70	78	
Injection site swelling (N=3075,1450,1446)	217	1450	1446	
Injection site pain (N=1580,422,429)	1580	422	429	
Any systemic	1487	604	569	
chills (N=1578,423,428)	154	23	18	
Myalgia (N=1578,423,429)	216	43	25	
Arthralgia (N=1578,423,429)	125	20	16	
Headache (N=1578,423,429)	282	46	38	
Fatigue (N=1578,423,430)	204	43	31	
Eating Habit (N=3076,1450,1446)	437	196	205	
Diarrhea (N=3075,1450,1447)	423	231	220	
Irritability (N=1496,1024,1013)	290	164	190	
Crying (N=1463,1001,990)	186	105	122	
Sleepiness (N=1495,1024,1012)	229	150	153	
Vomiting (N=3075,1451,1446)	249	100	104	
Fever ($\geq 38^{\circ}\text{C}$) (N=3074,1450,1446)	748	236	224	
Any other	1047	310	317	
Axillary Temperature ($\geq 40^{\circ}\text{C}$) (N=3074,1450,1446)	8	4	3	
Analgesic Antipyretic Med. used (N=3076,1448,1444)	984	285	282	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects Reporting Unsolicited Adverse Events After Vaccination

End point title	Number of Subjects Reporting Unsolicited Adverse Events After Vaccination
-----------------	---

End point description:

The number of subjects reporting any unsolicited adverse events (AEs) between Day 1 to Day 50, serious adverse events (SAEs), AE leading to withdrawal (WD), new onset of chronic disease (NOCD), adverse events of special interest following vaccination with aTIV or licensed comparator or TIV throughout the study (Day 1 to Day 394).

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 to Day 394

End point values	aTIV (6 to <72 Months)	Comparator TIV (6 to <72 Months)	TIV (6 to <72 Months)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	3123	1474	1477	
Units: Percentage of Subjects				
Any AEs (Day 1 to Day 50)	1541	859	808	
Possibly/probably related AEs(Day 1 to Day 50)	158	101	84	
Any SAEs	115	64	69	
Possibly/probably related SAE	1	0	0	
AE leading to WD	1	5	4	
NOCD	48	31	24	
AESI	1	0	0	
Deaths	1	3	4	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Solicited AEs collected from Day 1-7 after each vaccination, Unsolicited AEs, Adverse Events of Special Interest, New onset chronic disease, AEs leading to withdrawal and serious adverse events reported for through out the study (Day 1-Day 394).

Adverse event reporting additional description:

Analysis was done on Full Safety Set - Subjects who received at least one study vaccination and provided postbaseline safety data.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	15.1
--------------------	------

Reporting groups

Reporting group title	Comparator TIV (6 to <72 Months)
-----------------------	----------------------------------

Reporting group description:

Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29.

Reporting group title	ATIV (6 to <72 Months)
-----------------------	------------------------

Reporting group description:

Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29.

Reporting group title	TIV (6 to <72 Months)
-----------------------	-----------------------

Reporting group description:

Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29.

Serious adverse events	Comparator TIV (6 to <72 Months)	ATIV (6 to <72 Months)	TIV (6 to <72 Months)
Total subjects affected by serious adverse events			
subjects affected / exposed	64 / 1474 (4.34%)	115 / 3123 (3.68%)	69 / 1477 (4.67%)
number of deaths (all causes)	3	1	4
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute Lymphocytic Leukaemia			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	2 / 1477 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cholesteatoma			

subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accidental Exposure			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Animal Bite			
subjects affected / exposed	14 / 1474 (0.95%)	22 / 3123 (0.70%)	15 / 1477 (1.02%)
occurrences causally related to treatment / all	0 / 14	0 / 22	0 / 15
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Animal Scratch			
subjects affected / exposed	0 / 1474 (0.00%)	3 / 3123 (0.10%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Concussion			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Craniocerebral Injury			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Eye Injury			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Femur Fracture			

subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Forearm Fracture			
subjects affected / exposed	1 / 1474 (0.07%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head Injury			
subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus Fracture			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple Injuries			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radius Fracture			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull Fracture			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural Haemorrhage			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thermal Burn			

subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Finger Amputation			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Convulsion			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	2 / 1477 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile Convulsion			
subjects affected / exposed	3 / 1474 (0.20%)	13 / 3123 (0.42%)	4 / 1477 (0.27%)
occurrences causally related to treatment / all	0 / 3	0 / 13	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Drowning			
subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Immune system disorders			
Type III Immune Complex Mediated Reaction			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Coeliac Disease			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			

subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper Gastrointestinal Disorder Hemorrhage			
subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Adenoidal Hypertrophy			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	1 / 1474 (0.07%)	4 / 3123 (0.13%)	3 / 1477 (0.20%)
occurrences causally related to treatment / all	0 / 2	0 / 7	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Asthmatic Crisis			
subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atelectasis			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial Hyperreactivity			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchospasm			
subjects affected / exposed	0 / 1474 (0.00%)	3 / 3123 (0.10%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillary Hypertrophy			

subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Swelling Face			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Dermatitis Allergic			
subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	2 / 1477 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess Limb			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess Neck			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amoebiasis			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 1474 (0.07%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis Bacterial			

subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial Infection			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	1 / 1474 (0.07%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia			
subjects affected / exposed	6 / 1474 (0.41%)	4 / 3123 (0.13%)	3 / 1477 (0.20%)
occurrences causally related to treatment / all	0 / 6	0 / 4	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue Fever			
subjects affected / exposed	3 / 1474 (0.20%)	5 / 3123 (0.16%)	8 / 1477 (0.54%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea Infectious			
subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysentery			
subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis Viral			

subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	12 / 1474 (0.81%)	18 / 3123 (0.58%)	10 / 1477 (0.68%)
occurrences causally related to treatment / all	0 / 13	0 / 18	0 / 13
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Hepatitis A			
subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower Respiratory Tract Infection Viral			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mastoiditis			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Measles			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis Pneumococcal			
subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasopharyngitis			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis Media			

subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis Media Bacterial			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis Media Chronic			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parasitic Gastroenteritis			
subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngotonsillitis			
subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	13 / 1474 (0.88%)	26 / 3123 (0.83%)	12 / 1477 (0.81%)
occurrences causally related to treatment / all	0 / 14	0 / 28	0 / 13
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pneumonia Bacterial			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia Viral			

subjects affected / exposed	1 / 1474 (0.07%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis Acute			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory Syncytial Virus Infection			
subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory Tract Infection Viral			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Roseola			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	2 / 1474 (0.14%)	0 / 3123 (0.00%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Septic Shock			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Shigella Infection			
subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			

subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thypoid Fever			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	2 / 1477 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 1474 (0.00%)	2 / 3123 (0.06%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth Abscess			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper Respiratory Tract Infection			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Infection			
subjects affected / exposed	3 / 1474 (0.20%)	4 / 3123 (0.13%)	2 / 1477 (0.14%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral Infection			
subjects affected / exposed	2 / 1474 (0.14%)	2 / 3123 (0.06%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral Rash			

subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Hyponatraemia			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Malnutrition			
subjects affected / exposed	0 / 1474 (0.00%)	1 / 3123 (0.03%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic Acidosis			
subjects affected / exposed	0 / 1474 (0.00%)	0 / 3123 (0.00%)	1 / 1477 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Tetany			
subjects affected / exposed	1 / 1474 (0.07%)	0 / 3123 (0.00%)	0 / 1477 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Comparator TIV (6 to <72 Months)	ATIV (6 to <72 Months)	TIV (6 to <72 Months)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	917 / 1474 (62.21%)	2106 / 3123 (67.44%)	905 / 1477 (61.27%)
Nervous system disorders			
Headache			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	40 / 1474 (2.71%)	286 / 3123 (9.16%)	48 / 1477 (3.25%)
occurrences (all)	53	342	60
Somnolence			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	153 / 1474 (10.38%)	229 / 3123 (7.33%)	150 / 1477 (10.16%)
occurrences (all)	216	316	198
General disorders and administration site conditions			
Crying			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	124 / 1474 (8.41%)	186 / 3123 (5.96%)	105 / 1477 (7.11%)
occurrences (all)	162	225	139
Fatigue			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	31 / 1474 (2.10%)	204 / 3123 (6.53%)	43 / 1477 (2.91%)
occurrences (all)	45	259	57
Injection site erythema			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	102 / 1474 (6.92%)	312 / 3123 (9.99%)	109 / 1477 (7.38%)
occurrences (all)	122	378	130
Injection site hemorrhage			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	86 / 1474 (5.83%)	191 / 3123 (6.12%)	72 / 1477 (4.87%)
occurrences (all)	102	215	81
Injection site induration			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	67 / 1474 (4.55%)	258 / 3123 (8.26%)	62 / 1477 (4.20%)
occurrences (all)	78	293	71
Injection site pain			

alternative dictionary used: MedDRA 17.1 subjects affected / exposed occurrences (all)	189 / 1474 (12.82%) 248	851 / 3123 (27.25%) 1137	177 / 1477 (11.98%) 220
Injection site swelling alternative dictionary used: MedDRA 17.1 subjects affected / exposed occurrences (all)	43 / 1474 (2.92%) 47	217 / 3123 (6.95%) 238	34 / 1477 (2.30%) 36
Gastrointestinal disorders Diarrhea alternative dictionary used: MedDRA 17.1 subjects affected / exposed occurrences (all)	231 / 1474 (15.67%) 307	445 / 3123 (14.25%) 568	247 / 1477 (16.72%) 318
Vomiting alternative dictionary used: MedDRA 17.1 subjects affected / exposed occurrences (all) Pyrexia alternative dictionary used: MedDRA 17.1 subjects affected / exposed occurrences (all)	109 / 1474 (7.39%) 127 260 / 1474 (17.64%) 330	257 / 3123 (8.23%) 296 795 / 3123 (25.46%) 1003	107 / 1477 (7.24%) 129 279 / 1477 (18.89%) 331
Psychiatric disorders Irritability alternative dictionary used: MedDRA 17.1 subjects affected / exposed occurrences (all)	191 / 1474 (12.96%) 244	290 / 3123 (9.29%) 396	165 / 1477 (11.17%) 226
Eating Disorder alternative dictionary used: MedDRA 17.1 subjects affected / exposed occurrences (all)	206 / 1474 (13.98%) 273	437 / 3123 (13.99%) 541	197 / 1477 (13.34%) 254
Musculoskeletal and connective tissue disorders Myalgia alternative dictionary used: MedDRA 17.1			

subjects affected / exposed occurrences (all)	25 / 1474 (1.70%) 35	216 / 3123 (6.92%) 257	43 / 1477 (2.91%) 50
Infections and infestations			
Gastroenteritis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	84 / 1474 (5.70%)	112 / 3123 (3.59%)	70 / 1477 (4.74%)
occurrences (all)	91	117	74
Nasopharyngitis			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	175 / 1474 (11.87%)	291 / 3123 (9.32%)	151 / 1477 (10.22%)
occurrences (all)	206	349	174
Upper respiratory tract infection			
alternative dictionary used: MedDRA 17.1			
subjects affected / exposed	246 / 1474 (16.69%)	452 / 3123 (14.47%)	237 / 1477 (16.05%)
occurrences (all)	286	533	281

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/25223266>